We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
Read MoreHide Full Article
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
FOMO, or the fear of missing out, also plays a role in investing, particularly with tech giants and popular consumer-facing stocks.
What if you'd invested in Halozyme Therapeutics (HALO - Free Report) ten years ago? It may not have been easy to hold on to HALO for all that time, but if you did, how much would your investment be worth today?
Halozyme Therapeutics' Business In-Depth
With that in mind, let's take a look at Halozyme Therapeutics' main business drivers.
San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel treatments for oncology indications by targeting the tumor microenvironment. The company also licenses its novel drug delivery technology, ENHANZE, for subcutaneous (SC) administration of drugs.
The company’s ENHANZE drug delivery technology helps in developing the SC formulation of drugs. Several companies, including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others, are using this technology for developing the SC formulation of their currently marketed drugs. It also recognizes revenues from the sale of drug products to its collaboration partners for the development of drugs using its ENHANZE platform.
Halozyme now has several marketed partnered drugs based on this technology.
Halozyme currently earns royalties on sales of various commercial products by its partners. The ENHANZE platform was developed based on the company’s patented recombinant human hyaluronidase enzyme (rHuPH20).
The company’s commercial portfolio of products includes Hylenex Recombinant and Xyosted, with the latter acquired from Antares Pharma in 2022.
Halozyme derives the majority of its revenues from royalties on sales of partnered drugs. Royalties constituted more than 55% of the company’s total revenues in 2025. Halozyme generated total revenues of $1.39 billion in 2025, up 38% year over year.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Halozyme Therapeutics, if you bought shares a decade ago, you're likely feeling really good about your investment today.
A $1000 investment made in September 2016 would be worth $10,866.33, or a gain of 986.63%, as of September 1, 2026, according to our calculations. This return excludes dividends but includes price appreciation.
In comparison, the S&P 500's gained 254.05% and the price of gold went up 225.98% over the same time frame.
Going forward, analysts are expecting more upside for HALO.
Halozyme's second-quarter earnings and revenues beat estimates. The company has collaboration deals related to its ENHANZE technology with several large pharma companies that generate royalties and milestone payments. This, in return, is driving the company's top line. Robust demand for argenx's Vyvgart Hytrulo and the subcutaneous formulation of J&J's Darzalex is boosting royalties and the top line. The momentum is likely to continue for the rest of 2026. Halozyme is also focused on signing new collaboration deals to aid growth. However, blockbuster drugs like Herceptin and Rituxan, which utilize ENHANZE technology, are now facing biosimilar competition, resulting in potential decreased revenues from royalties. High dependence on partners for revenues in the form of royalties remains a major concern.
The stock is up 29.44% over the past four weeks, and no earnings estimate has gone lower in the past two months, compared to 1 higher, for fiscal 2026. The consensus estimate has moved up as well.
View the Zacks #1 Rank List
Image: Bigstock
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
FOMO, or the fear of missing out, also plays a role in investing, particularly with tech giants and popular consumer-facing stocks.
What if you'd invested in Halozyme Therapeutics (HALO - Free Report) ten years ago? It may not have been easy to hold on to HALO for all that time, but if you did, how much would your investment be worth today?
Halozyme Therapeutics' Business In-Depth
With that in mind, let's take a look at Halozyme Therapeutics' main business drivers.
San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel treatments for oncology indications by targeting the tumor microenvironment. The company also licenses its novel drug delivery technology, ENHANZE, for subcutaneous (SC) administration of drugs.
The company’s ENHANZE drug delivery technology helps in developing the SC formulation of drugs. Several companies, including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others, are using this technology for developing the SC formulation of their currently marketed drugs. It also recognizes revenues from the sale of drug products to its collaboration partners for the development of drugs using its ENHANZE platform.
Halozyme now has several marketed partnered drugs based on this technology.
Halozyme currently earns royalties on sales of various commercial products by its partners. The ENHANZE platform was developed based on the company’s patented recombinant human hyaluronidase enzyme (rHuPH20).
The company’s commercial portfolio of products includes Hylenex Recombinant and Xyosted, with the latter acquired from Antares Pharma in 2022.
Halozyme derives the majority of its revenues from royalties on sales of partnered drugs. Royalties constituted more than 55% of the company’s total revenues in 2025. Halozyme generated total revenues of $1.39 billion in 2025, up 38% year over year.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Halozyme Therapeutics, if you bought shares a decade ago, you're likely feeling really good about your investment today.
A $1000 investment made in September 2016 would be worth $10,866.33, or a gain of 986.63%, as of September 1, 2026, according to our calculations. This return excludes dividends but includes price appreciation.
In comparison, the S&P 500's gained 254.05% and the price of gold went up 225.98% over the same time frame.
Going forward, analysts are expecting more upside for HALO.
Halozyme's second-quarter earnings and revenues beat estimates. The company has collaboration deals related to its ENHANZE technology with several large pharma companies that generate royalties and milestone payments. This, in return, is driving the company's top line. Robust demand for argenx's Vyvgart Hytrulo and the subcutaneous formulation of J&J's Darzalex is boosting royalties and the top line. The momentum is likely to continue for the rest of 2026. Halozyme is also focused on signing new collaboration deals to aid growth. However, blockbuster drugs like Herceptin and Rituxan, which utilize ENHANZE technology, are now facing biosimilar competition, resulting in potential decreased revenues from royalties. High dependence on partners for revenues in the form of royalties remains a major concern.
The stock is up 29.44% over the past four weeks, and no earnings estimate has gone lower in the past two months, compared to 1 higher, for fiscal 2026. The consensus estimate has moved up as well.